Integration of apolipoprotein B into the SCORE2 framework: implications for cardiovascular risk prediction

被引:0
|
作者
Wong, Wen Kai [1 ,2 ,3 ]
Takeuchi, Fumihiko [1 ,4 ,5 ]
Thao, Le Thi Phuong [6 ]
Nicholls, Stephen J. [7 ,8 ]
Chew, Derek P. [7 ,8 ]
Peter, Karlheinz [1 ,2 ]
机构
[1] Univ Melbourne, Fac Med Dent & Hlth Sci, Grattan St, Parkville, Vic 3010, Australia
[2] Baker Heart & Diabet Inst, Atherothrombosis & Vasc Biol Lab, 75 Commercial Rd, Melbourne, Vic 3004, Australia
[3] Imperial Coll London, Fac Med, London, England
[4] Baker Heart & Diabet Inst, Syst Genom Lab, Melbourne, Australia
[5] Baker Heart & Diabet Inst, Cambridge Baker Syst Genom Initiat, Melbourne, Australia
[6] Monash Univ, Sch Publ Hlth & Prevent Med, Melbourne, Australia
[7] Monash Univ, Victorian Heart Inst, Melbourne, Australia
[8] Monash Hlth, Victorian Heart Hosp, Melbourne, Australia
基金
英国医学研究理事会;
关键词
Apolipoprotein B (ApoB); Systematic Coronary Risk Evaluation 2 (SCORE2); Cardiovascular risk prediction; UK Biobank; CORONARY-HEART-DISEASE; MYOCARDIAL-INFARCTION; LDL-CHOLESTEROL; I RATIO; A-I; PREVENTION; GUIDELINES; MANAGEMENT; SOCIETY; MARKERS;
D O I
10.1093/eurjpc/zwaf039
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims To evaluate whether integrating Apolipoprotein B (ApoB) into the Systematic Coronary Risk Evaluation 2 (SCORE2) cardiovascular risk prediction framework improves its predictive accuracy and clinical applicability within the UK Biobank population. Methods and results A 10-year prospective cohort study was conducted with 448 303 UK Biobank participants eligible for SCORE2 calculation. Three approaches were employed: (i) threshold analysis to determine the optimal ApoB cutoff for cardiovascular disease (CVD) risk prediction using Youden's Index, (ii) assessment of the synergistic effect of SCORE2 and ApoB through concordant and discordant classifications, and (iii) recalibration of the SCORE2 model by incorporating ApoB as an additional predictor. Each 0.2 g/L increase in ApoB was associated with an increased subdistribution hazard for CVD events [subdistribution hazard ratio (SHR): 1.13; 95% CI: 1.11-1.14, P < 0.001], accounting for non-cardiovascular death as a competing risk. Threshold analysis identified an optimal ApoB cutoff at 1.18 g/L; however, it demonstrated limited discriminatory performance (area under the curve 0.54), with low sensitivity (32.4%), and moderate specificity (74.4%). Individuals with both low ApoB (<1.18 g/L) and low SCORE2 risk (<5%) had a lower CVD incidence rate (232.51 per 100 000 person-years) compared with those identified as low risk by SCORE2 alone (253.69 per 100 000 person-years). Integration of ApoB into the SCORE2 model did not significantly improve the model discrimination, calibration, and net reclassification improvement. Conclusion Apolipoprotein B exhibited a dose-response relationship with cardiovascular risk but had limited standalone predictive utility within the UK Biobank population. However, combining ApoB with SCORE2 thresholds improved the identification of low-risk individuals, suggesting a complementary role for ApoB in refining cardiovascular risk stratification.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] The Updated Cardiovascular Risk Tool SCORE2 Provides No Advantage in Identifying Patients with Gout and Carotid Atheroma Plaques
    Tovar-Sugranes, Ernesto
    Lopez-Gonzalez, Maria-Carmen
    Rodriguez-Alvear, Cristina
    Perea-Martinez, Elisabet
    Andres, Mariano
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 3611 - 3612
  • [42] Validation of SCORE2 on a sample from the Russian population and adaptation for the very high cardiovascular disease risk region
    Svinin, Gleb E.
    Kutsenko, Vladimir A.
    Shalnova, Svetlana A.
    Yarovaya, Elena B.
    Imaeva, Asiia E.
    Balanova, Yulia A.
    Kapustina, Anna V.
    Muromtseva, Galina A.
    Drapkina, Oxana M.
    PLOS ONE, 2024, 19 (04):
  • [43] SCORE and SCORE2 Comparison in Cardiovascular Risk Estimation in Rheumatoid Arthritis Patients: A Cross-sectional Study Including Carotid Ultrasound
    Campos Fernandez, Cristina
    Martinez Calabuig, Pablo
    Fragio Gil, Jorge Juan
    Gonzalez Mazario, Roxana
    Roman Ivorra, Jose Andres
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 4203 - 4205
  • [44] Prediction of cardiovascular risk in patients type 2 diabetes using the SCORE2-Diabetes risk score
    Cavender, M.
    Sorensen, A.
    Bonaca, M.
    Cannon, C.
    Clemmensen, K.
    Buse, J.
    Kvist, K.
    EUROPEAN HEART JOURNAL, 2024, 45
  • [45] Prognostic change of adding coronary calcium score and genetic risk score to European SCORE2 in a moderate risk region
    Temtem, M.
    Palma Dos Reis, R.
    Serrao, M.
    Santos, M.
    Sa, D.
    Sousa, F.
    Rodrigues, M.
    Freitas, S.
    Henriques, E.
    Borges, S.
    Guerra, G.
    Ornelas, I.
    Drumond, A.
    Sousa, A. C.
    Mendonca, M. I.
    EUROPEAN HEART JOURNAL, 2023, 44
  • [46] Use of coronary calcium score to refine the cardiovascular risk classification of the new SCORE2 and SCORE2-OP algorithms in patients undergoing coronary CT angiography
    Paiva, M.
    Gomes, D.
    Freitas, P.
    Presume, P.
    Santos, R.
    Lopes, P.
    Matos, D.
    Guerreiro, S.
    Abecasis, J.
    Santos, A.
    Saraiva, C.
    Mendes, M.
    Ferreira, A.
    EUROPEAN HEART JOURNAL, 2022, 43 : 194 - 194
  • [47] SCORE2 Asia-Pacific: a comprehensive approach to prevention of cardiovascular disease
    Hageman, Steven H. J.
    Johar, Sofian
    Visseren, Frank L. J.
    EUROPEAN HEART JOURNAL, 2025,
  • [48] Improving 10-year cardiovascular risk prediction in apparently healthy people: flexible addition of risk modifiers on top of SCORE2( vol 30, pg 1705, 2023)
    Hageman, Steven H. J.
    Petitjean, Carmen
    Pennells, Lisa
    Kaptoge, Stephen
    Pajouheshnia, Romin
    Tillmann, Taavi
    Blaha, Michael J.
    McClelland, Robyn L.
    Matsushita, Kunihiro
    Nambi, Vijay
    Klungel, Olaf H.
    Souverein, Patrick C.
    van der Schouw, Yvonne T.
    Verschuren, W. M. Monique
    Lehmann, Nils
    Erbel, Raimund
    Joeckel, Karl-Heinz
    Di Angelantonio, Emanuele
    Visseren, Frank L. J.
    Dorresteijn, Jannick A. N.
    EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2024, 31 (13) : e103 - e103
  • [49] Cardiovascular diseases: protein score for risk prediction?
    Simon, Annika
    DIABETOLOGIE UND STOFFWECHSEL, 2024, 19 (01) : 25 - 26
  • [50] How the new ESC cardiovascular risk chart, SCORE2, identifies additional high risk patients in a population free of cardiovascular disease with large waist circumference
    Douhard, Sarah
    Snel, Marc
    Van Gaal, Luc
    Brohet, Christian
    Scheen, Andre
    Demeure, Fabian
    Descamps, Olivier S.
    ACTA CLINICA BELGICA, 2022, 77 : 24 - 25